Published in Cancer Genet Cytogenet on September 01, 1992
Sensitive detection of chromosome copy number aberrations in prostate cancer by fluorescence in situ hybridization. Am J Pathol (1994) 0.93
Fluorescence in situ hybridization evaluation of chromosome deletion patterns in prostate cancer. Am J Pathol (1996) 0.86
Application of fluorescence in situ hybridisation to chromosome analysis of aged bone marrow smears. J Clin Pathol (1994) 0.85
Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor. Nat Med (2000) 3.26
Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology (1996) 2.77
Results of radical prostatectomy in men with clinically localized prostate cancer. JAMA (1996) 2.74
Activation of EphA receptor tyrosine kinase inhibits the Ras/MAPK pathway. Nat Cell Biol (2001) 2.25
Human cell hybrids: analysis of transformation and tumorigenicity. Science (1982) 2.16
Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine. Am J Pathol (2001) 2.15
Proteinchip(R) surface enhanced laser desorption/ionization (SELDI) mass spectrometry: a novel protein biochip technology for detection of prostate cancer biomarkers in complex protein mixtures. Prostate Cancer Prostatic Dis (1999) 1.73
Results of a multicenter trial using the BTA test to monitor for and diagnose recurrent bladder cancer. J Urol (1995) 1.71
Vitamin D and prostate cancer: 1,25 dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines. Endocrinology (1993) 1.68
Expression and characterization of recombinant type 2 3 alpha-hydroxysteroid dehydrogenase (HSD) from human prostate: demonstration of bifunctional 3 alpha/17 beta-HSD activity and cellular distribution. Mol Endocrinol (1997) 1.59
Prostate-specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasma. J Clin Endocrinol Metab (1992) 1.53
Role of glutathione depletion and reactive oxygen species generation in apoptotic signaling in a human B lymphoma cell line. Cell Death Differ (2002) 1.48
Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. PROSCAR long-term efficacy and safety study. J Urol (2000) 1.47
Nocturnal nasal ventilation for treatment of patients with hypercapnic respiratory failure. Mayo Clin Proc (1991) 1.47
Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues. Urol Oncol (2011) 1.45
Prostate-specific antigen for pretreatment prediction and posttreatment evaluation of outcome after definitive irradiation for prostate cancer. Int J Radiat Oncol Biol Phys (1995) 1.45
Consultation for asthma: results of a generalist survey. Ann Allergy Asthma Immunol (1999) 1.42
Pulmonary metastases from prostate cancer. Cancer (1995) 1.42
Clonal growth of human keratinocytes with small amounts of dialyzed serum. In Vitro (1980) 1.41
Insulin-like growth factors (IGFs), IGF receptors, and IGF-binding proteins in primary cultures of prostate epithelial cells. J Clin Endocrinol Metab (1991) 1.40
Reduced 1alpha-hydroxylase activity in human prostate cancer cells correlates with decreased susceptibility to 25-hydroxyvitamin D3-induced growth inhibition. Cancer Res (2001) 1.36
Growth and differentiation of human keratinocytes without a feeder layer or conditioned medium. In Vitro (1980) 1.33
SMAD3 represses androgen receptor-mediated transcription. Cancer Res (2001) 1.32
Keratin immunoreactivity in the benign and neoplastic human prostate. Cancer Res (1985) 1.32
Malignant pericardial effusion as initial solitary site of metastasis from transitional cell carcinoma of the bladder. Urology (1995) 1.26
Elevated levels of insulin-like growth factor-binding protein-2 in the serum of prostate cancer patients. J Clin Endocrinol Metab (1993) 1.26
Biological effects of prostate specific antigen as an insulin-like growth factor binding protein-3 protease. J Endocrinol (1994) 1.25
Goserelin versus orchiectomy in the treatment of advanced prostate cancer: final results of a randomized trial. Zoladex Prostate Study Group. Urology (1995) 1.23
Spontaneous regression of metastatic renal cell carcinoma. Urology (1982) 1.22
Quality of life after treatment for localized prostate cancer: differences based on treatment modality. J Urol (2001) 1.22
Down-regulation of a calmodulin-related gene during transformation of human mammary epithelial cells. Proc Natl Acad Sci U S A (1990) 1.19
Selection of human cervical epithelial cells that possess reduced apoptotic potential to low-oxygen conditions. Cancer Res (1997) 1.19
Anchorage-independent growth of normal human fibroblasts. Proc Natl Acad Sci U S A (1981) 1.13
Preferential production of latent transforming growth factor beta-2 by primary prostatic epithelial cells and its activation by prostate-specific antigen. J Cell Physiol (2005) 1.12
Results of radical prostatectomy in men with locally advanced prostate cancer: multi-institutional pooled analysis. Eur Urol (1997) 1.11
Prostate specific antigen cleaves parathyroid hormone-related protein in the PTH-like domain: inactivation of PTHrP-stimulated cAMP accumulation in mouse osteoblasts. J Urol (1996) 1.11
Quantitation of serum prostate-specific membrane antigen by a novel protein biochip immunoassay discriminates benign from malignant prostate disease. Cancer Res (2001) 1.10
Four cases of metastases to the penis and a review of the literature. J Urol (1984) 1.10
The adrenal gland and renal cell carcinoma: is ipsilateral adrenalectomy a necessary component of radical nephrectomy? J Urol (1986) 1.09
Two mutations identified in the androgen receptor of the new human prostate cancer cell line MDA PCa 2a. J Urol (1999) 1.08
Tuberculosis-related deaths in Queensland, Australia, 1989-1998: characteristics and risk factors. Int J Tuberc Lung Dis (2003) 1.08
The IGF axis in the prostate. Horm Metab Res (1994) 1.08
Combined androgen blockade with nonsteroidal antiandrogens for advanced prostate cancer: a systematic review. Urology (2001) 1.06
Frequency and pattern of karyotypic abnormalities in human prostate cancer. Cancer Res (1990) 1.04
Tumor-selective killing by selenite in patient-matched pairs of normal and malignant prostate cells. Prostate (2006) 1.03
p16INK4A mediates cyclin dependent kinase 4 and 6 inhibition in senescent prostatic epithelial cells. Cancer Res (2000) 1.03
Serum-free growth of adult human prostatic epithelial cells. In Vitro Cell Dev Biol (1986) 1.02
Characteristics of spinal cord compression in adenocarcinoma of prostate. Urology (1986) 1.01
Induction of androgen receptor by 1alpha,25-dihydroxyvitamin D3 and 9-cis retinoic acid in LNCaP human prostate cancer cells. Endocrinology (1999) 1.01
Randomized intergroup comparison of bacillus calmette-guerin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder a southwest oncology group study. Urol Oncol (2011) 1.00
Improved detection of recurrent bladder cancer using the Bard BTA stat Test. Urology (1997) 1.00
1alpha,25-dihydroxyvitamin D3 actions in LNCaP human prostate cancer cells are androgen-dependent. Endocrinology (1997) 0.99
Actions of vitamin D3, analogs on human prostate cancer cell lines: comparison with 1,25-dihydroxyvitamin D3. Endocrinology (1995) 0.98
Comparative quality-of-life analysis after radical prostatectomy or external beam radiation for localized prostate cancer. Urology (1999) 0.98
Re: Intravesical bacillus Calmette-Guerin therapy and associated granulomatous renal masses. J Urol (1987) 0.97
Zoladex versus orchiectomy in treatment of advanced prostate cancer: a randomized trial. Zoladex Prostate Study Group. Urology (1991) 0.95
Conservative surgical therapy for penile and urethral carcinoma. Urology (1999) 0.95
Clonal growth of human prostatic epithelial cells is stimulated by fibroblasts. Prostate (1989) 0.95
1alpha,25-dihydroxyvitamin D3 inhibits prostate cancer cell growth by androgen-dependent and androgen-independent mechanisms. Endocrinology (2000) 0.95
Torsional response and stiffening of individual multiwalled carbon nanotubes. Phys Rev Lett (2002) 0.94
Lipofection-mediated immortalization of human prostatic epithelial cells of normal and malignant origin using human papillomavirus type 18 DNA. Cancer Res (1994) 0.94
The use of microsurgical denervation of the spermatic cord for orchialgia. Trans Am Assoc Genitourin Surg (1978) 0.94
Effect of local tumor control on distant metastasis and survival in prostatic adenocarcinoma. Urology (1987) 0.94
Immediate adjuvant intravesical chemotherapy after transurethral resection of bladder tumor. Curr Opin Urol (1998) 0.94
Human papillomavirus detection by polymerase chain reaction in benign and malignant prostate tissue is dependent on the primer set utilized. Urology (1997) 0.92
Attenuated response of p53 and p21 in primary cultures of human prostatic epithelial cells exposed to DNA-damaging agents. Cancer Res (1995) 0.92
Characterization of human keratinocyte X HeLa somatic cell hybrids. Int J Cancer (1981) 0.92
Renal metastases from carcinoma of the lung. Br J Urol (1986) 0.92
Comparison of goserelin and leuprolide in combined androgen blockade therapy. Urology (1998) 0.91
Determination of the "reflex range" and appropriate cutpoints for percent free prostate-specific antigen in 413 men referred for prostatic evaluation using the AxSYM system. Urology (1997) 0.91
Characterization of cultured human prostatic epithelial cells by cluster designation antigen expression. Cell Tissue Res (2001) 0.91
Decreased expression of Wilms' tumor gene WT-1 and elevated expression of insulin growth factor-II (IGF-II) and type 1 IGF receptor genes in prostatic stromal cells from patients with benign prostatic hyperplasia. J Clin Endocrinol Metab (1997) 0.91
Prostatic involvement by transitional cell carcinoma: pathogenesis, patterns and prognosis. J Urol (1977) 0.91
Insulin-like growth factor axis abnormalities in prostatic stromal cells from patients with benign prostatic hyperplasia. J Clin Endocrinol Metab (1994) 0.90
Histochemical studies of the myocardium and conduction system in acquired iron-storage disease. Circulation (1967) 0.90
Transformation of human neonatal prostate epithelial cells by strontium phosphate transfection with a plasmid containing SV40 early region genes. Cancer Res (1989) 0.89
Calcium signaling in prostate cancer cells: evidence for multiple receptors and enhanced sensitivity to bombesin/GRP. Prostate (1997) 0.89
Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia. Br J Cancer (1998) 0.89
Additional bacillus Calmette-Guérin therapy for recurrent transitional cell carcinoma after an initial complete response. Urology (1997) 0.89
The role of differentiation in the suppression of tumorigenicity in human cell hybrids. Int J Cancer (1982) 0.88
Management of patients with Bacilli Calmette-Guérin-refractory carcinoma in situ of the urinary bladder: cost implications of a clinical trial for valrubicin. Clin Ther (2000) 0.88
Giant hydronephrosis of a duplex system associated with ureteral ectopia. J Urol (1989) 0.87
Bacillus Calmette-Guerin for superficial transitional cell carcinoma of the bladder. J Urol (1986) 0.87
Estrogen receptor activity in a case of Hodgkin's disease. Ann Intern Med (1981) 0.87
Prostate-specific membrane antigen levels in sera from healthy men and patients with benign prostate hyperplasia or prostate cancer. Clin Cancer Res (1999) 0.86
U73122 and U73343 inhibit receptor-mediated phospholipase D activation downstream of phospholipase C in CHO cells. Eur J Pharmacol (1998) 0.85
Tumor-suppression function of transcription factor USF2 in prostate carcinogenesis. Oncogene (2006) 0.84
A dose-response study of the effect of flutamide on benign prostatic hyperplasia: results of a multicenter study. Urology (1996) 0.84
Does prolonged combined androgen blockade have survival benefits over short-term combined androgen blockade therapy? Urology (2000) 0.84
Activated Ki-ras oncogene in human prostatic adenocarcinoma. Prostate (1987) 0.84
Serum levels of endothelial and neural cell adhesion molecules in prostate cancer. Prostate (1997) 0.84
Prognosis in patients with local recurrence after definitive irradiation for prostatic carcinoma. Cancer (1989) 0.83
Outcomes after intravesical bacillus Calmette-Guerin are not affected by substaging of high grade T1 transitional cell carcinoma. J Urol (2000) 0.83
Attachment of periosteal grafts to articular cartilage with fibrin sealant. J Biomed Mater Res (1999) 0.83
The effect of TURP on prognosis in prostatic carcinoma. Int J Radiat Oncol Biol Phys (1987) 0.83
Intravesical chemotherapy and immunotherapy for superficial tumors Basic mechanism of action and future direction. Urol Oncol (2011) 0.83